Quarterly report [Sections 13 or 15(d)]

Condensed Consolidated Statements of Changes in Shareholders' Equity (Deficit)

v3.26.3
Condensed Consolidated Statements of Changes in Shareholders' Equity (Deficit) - USD ($)
Common Shares
July 22, 2025 Exercise of Discounted Warrants And Pipe Offering
Common Shares
July 28, 2025 Exercise of Discounted Warrants And Pipe Offering
Common Shares
January 2026 PIPE
Common Shares
Additional Paid-in Capital
July 22, 2025 Exercise of Discounted Warrants And Pipe Offering
Additional Paid-in Capital
July 28, 2025 Exercise of Discounted Warrants And Pipe Offering
Additional Paid-in Capital
January 2026 PIPE
Additional Paid-in Capital
Accumulated Other Comprehensive Loss
Accumulated Deficit
July 22, 2025 Exercise of Discounted Warrants And Pipe Offering
July 28, 2025 Exercise of Discounted Warrants And Pipe Offering
January 2026 PIPE
Total
Balance at the beginning at Dec. 31, 2024               $ 107,546,433 $ (371,184) $ (90,687,073)       $ 16,488,176
Balance at the beginning (in shares) at Dec. 31, 2024       1,307,520                    
Condensed Consolidated Statements of Changes in Shareholders' Equity (Deficit)                            
Share-based compensation expense               654,457           654,457
Issuance of Common Shares from ATM Offering, net of issuance costs               708,468           708,468
Issuance of Common Shares from ATM Offering, net of issuance costs (in shares)       40,795                    
Issuance of pre-funded warrants from July 2025 Registered Direct Offering, net of issuance costs               697,658           697,658
Issuance of Common Shares from exercise of pre-funded warrants               3,050           3,050
Issuance of Common Shares from exercise of pre-funded warrants (in shares)       51,197                    
Proceeds from issuance of Common Shares and warrants from discounted warrant exercise and PIPE, net of issuance costs         $ 8,391,027 $ 11,144,468         $ 8,391,027 $ 11,144,468    
Proceeds from issuance of Common Shares and warrants from discounted warrant exercise and PIPE, net of issuance costs (in shares) 336,449 416,436                        
Re-measurement of liability-classified C$ stock options               145,110           145,110
Net loss                   (29,045,059)       (29,045,059)
Balance at the end at Sep. 30, 2025               129,290,671 (371,184) (119,732,132)       9,187,355
Balance at the end (in shares) at Sep. 30, 2025       2,152,397                    
Balance at the beginning at Dec. 31, 2024               107,546,433 (371,184) (90,687,073)       16,488,176
Balance at the beginning (in shares) at Dec. 31, 2024       1,307,520                    
Balance at the end at Dec. 31, 2025               129,518,812 (371,184) (130,406,220)       (1,258,592)
Balance at the end (in shares) at Dec. 31, 2025       2,152,397                    
Balance at the beginning at Jun. 30, 2025               108,140,611 (371,184) (108,152,006)       (382,579)
Balance at the beginning (in shares) at Jun. 30, 2025       1,307,520                    
Condensed Consolidated Statements of Changes in Shareholders' Equity (Deficit)                            
Share-based compensation expense               197,147           197,147
Issuance of Common Shares from ATM Offering, net of issuance costs               708,468           708,468
Issuance of Common Shares from ATM Offering, net of issuance costs (in shares)       40,795                    
Issuance of pre-funded warrants from July 2025 Registered Direct Offering, net of issuance costs               697,658           697,658
Issuance of Common Shares from exercise of pre-funded warrants               3,050           3,050
Issuance of Common Shares from exercise of pre-funded warrants (in shares)       51,197                    
Proceeds from issuance of Common Shares and warrants from discounted warrant exercise and PIPE, net of issuance costs         $ 8,391,027 $ 11,144,468         $ 8,391,027 $ 11,144,468    
Proceeds from issuance of Common Shares and warrants from discounted warrant exercise and PIPE, net of issuance costs (in shares) 336,449 416,436                        
Re-measurement of liability-classified C$ stock options               8,242           8,242
Net loss                   (11,580,126)       (11,580,126)
Balance at the end at Sep. 30, 2025               129,290,671 (371,184) (119,732,132)       9,187,355
Balance at the end (in shares) at Sep. 30, 2025       2,152,397                    
Balance at the beginning at Dec. 31, 2025               129,518,812 (371,184) (130,406,220)       (1,258,592)
Balance at the beginning (in shares) at Dec. 31, 2025       2,152,397                    
Condensed Consolidated Statements of Changes in Shareholders' Equity (Deficit)                            
Share-based compensation expense               1,080,958           1,080,958
Issuance of Common Shares from ATM Offering, net of issuance costs             $ 70,081,309 21,072         $ 70,081,309 21,072
Issuance of Common Shares from ATM Offering, net of issuance costs (in shares)     6,815,296 1,407                    
Re-measurement of liability-classified C$ stock options               (27,186)           (27,186)
Net loss                   (28,135,897)       (28,135,897)
Balance at the end at Sep. 30, 2026               200,674,965 (371,184) (158,542,117)       41,761,664
Balance at the end (in shares) at Sep. 30, 2026       8,969,100                    
Balance at the beginning at Jun. 30, 2026               200,150,367 (371,184) (150,380,249)       49,398,934
Balance at the beginning (in shares) at Jun. 30, 2026       8,967,693                    
Condensed Consolidated Statements of Changes in Shareholders' Equity (Deficit)                            
Share-based compensation expense               482,640           482,640
Issuance of Common Shares from ATM Offering, net of issuance costs               21,072           21,072
Issuance of Common Shares from ATM Offering, net of issuance costs (in shares)       1,407                    
Re-measurement of liability-classified C$ stock options               20,886           20,886
Net loss                   (8,161,868)       (8,161,868)
Balance at the end at Sep. 30, 2026               $ 200,674,965 $ (371,184) $ (158,542,117)       $ 41,761,664
Balance at the end (in shares) at Sep. 30, 2026       8,969,100